Company: AIBT
Filing Date: 2025-07-03
Form Type: 253G2
Source: 0001096906-25-001087
Chunk: 5

Company: AIBOTICS, INC.
Filing Date: 2025-07-03
Form: 253G2
Chunk 5
---
 then issued and outstanding shares of our common stock. In May 2021 we changed our name to Mycotopia Therapies, Inc. and our trading symbol became TPIA. On August 9, 2024, we increased our authorized Common shares to 467,000,000 common shares. On February 3, 2025, we changed our name to Aibotics, Inc. and our trading symbol to AIBT. On March 14, 2025, the Company’s board approved an increase in the company’s common shares to 7,500,000,000. We have two subsidiaries, NPD Genius, LLC (“NPD”) and Mycotopia Therapies, Inc., a Florida corporation. Our board of directors consists of Ben Kaplan and Mark Croskey. In December 2020, we entered into definitive agreements with Ehave, Inc., an Ontario corporation, Mycotopia Therapies Inc., a Florida corporation and wholly owned subsidiary of Ehave, Inc., and the former and current directors of 20/20 Global that provide for the 20/20 Global’s purchase of all of the outstanding stock of Mycotopia Therapies, Inc. from Ehave, Inc. On November 28, 2023, Aibotics, Inc. (the “Company”) entered into an Asset Sale and Purchase Agreement (the “Asset Purchase Agreement”) and Intellectual Property Assignment Agreement (the “IP Assignment”) with Philon Labs, LLC (“Philon Labs”) for the acquisition of certain assets of Philon Labs including the intellectual property related to its “Phill Robot” and “Milky Way” products. As a result, the Company ceased all operations in the psychedelics business. In consideration for the acquisition of the Assets, Aibotics, issued a new class of Preferred Stock (the “Preferred Stock”) with a face value of $2,000,000, convertible into shares of the Company’s Common Stock (the “Common Stock”). All shares of Preferred Stock and Common Stock issued in conjunction with the transaction are “restricted securities,” as defined in Rule 144 under the Securities Act of 1933, as amended (the “Securities Act”). The Company also entered into employment agreements that have revenue-based incentives connected to sales generated by the assets acquired. The incentives could result in the employees receiving up to $7,000,000 of the Preferred Stock over a three-year period. References to “us,” “we,” “our,” and correlative terms